期刊
CLINICAL LIPIDOLOGY
卷 4, 期 5, 页码 663-675出版社
FUTURE MEDICINE LTD
DOI: 10.2217/CLP.09.42
关键词
anticancer; antiparasitic; arsenic; arsenolipid; arsonolipid; arsonoliposomes; biodistribution; drug carrier; drug delivery; liposomes
Arsonoliposomes are arsenic-containing liposomes that incorporate novel arsenic-containing lipids (arsonolipids) in their lipid bilayers. In vitro and in vivo studies have demonstrated that some arsonoliposome types have interesting anticancer and antiprotozoal activity. Their anticancer activity may be linked with the reduction of their arsenic content to its more toxic form (from As[V] to As[III]). This reduction is enhanced in areas where increased concentrations of thiol-containing compounds (such as glutathione) prevail (which is the case for some types of cancer cells). The physicochemical characteristics, the in vivo distribution and kinetics and the antiprotozoal activity of arsonoliposomes were found to be influenced by the lipid composition of their membrane, while their anticancer activity was minimally - if at all - affected. Currently, the in vivo activity and toxicity of specific arsonoliposome types is being evaluated in in vivo cancer models, while combinations of arsonoliposomes with cytotoxic agents are being evaluated in vitro.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据